Grant: Project Grant
University of Alberta
$100,000.00
Targeting PDGFRa using PET Imaging to Diagnose Metastatic Papillary Thyroid Cancer and Improve Treatment
FY 2017-18
Summary
We have identified a marker of aggressive disease in papillary thyroid cancer that can be used as a means to find metastatic disease. Metastatic disease is common but often hard to find in thyroid cancer patients. We have created an imaging tool that can not only find where metastases are using a PET scan, but also can determine if the disease is sensitive to radioactive iodine. This new imaging scan can be used to map out a treatment plan that avoids high doses of unnecessary, or ineffective, radioactive iodine therapy in a cancer that affects more than 7000 patients a year in Canada. Our goal is to develop a diagnostic test that helps avoid over-treatment for thyroid cancer patients.
Department
Program
Project Grant
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
379019
Name
McMullen Todd
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Medical Physics & Imaging 2
Projecttitle
Targeting PDGFRa using PET Imaging to Diagnose Metastatic Papillary Thyroid Cancer and Improve Treatment
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cell Differentiation; Immuno-Pet-Pdgfra; Papillary Thyroid Cancer; Radiopharmaceutical
Abstract
We have identified a marker of aggressive disease in papillary thyroid cancer that can be used as a means to find metastatic disease. Metastatic disease is common but often hard to find in thyroid cancer patients. We have created an imaging tool that can not only find where metastases are using a PET scan, but also can determine if the disease is sensitive to radioactive iodine. This new imaging scan can be used to map out a treatment plan that avoids high doses of unnecessary, or ineffective, radioactive iodine therapy in a cancer that affects more than 7000 patients a year in Canada. Our goal is to develop a diagnostic test that helps avoid over-treatment for thyroid cancer patients.
Competitiondate
201710
Approvedterm2
1 yr 0 mth
Pinamesdelim
McMullen, Todd
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
